SCHEMBL24287953

SCHEMBL24287953

O=Nc1ccc(C(=O)N2CCCC2)cc1OC(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 12/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MLYCD O95822 1/20 0.41
▸ RECQL P46063 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20073407 0.81 HPGD (0.47) HPGDL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL24287952 0.79 PDE4A (0.43) L3MBTL1ALDH1A1GAAHTTRAB9A
SCHEMBL20225770 0.77 MEN1 (0.54) HPGDL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL24287954 0.75 MAPT (0.44) HPGDL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL29944141 0.73 HPGD (0.65) HPGDL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL20750534 0.71 KDM4E (0.44) L3MBTL1ALDH1A1MEN1KMT2AHTT
SCHEMBL1911937 0.71 KMT2A (0.64) HPGDL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL16982497 0.70 KMT2A (0.53) HPGDL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL20750380 0.70 SIGMAR1 (0.46) HPGDHTTRAB9AKDM4ELMNA
SCHEMBL17076877 0.70 LRRK2 (0.51) HPGDL3MBTL1KMT2AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HPGD 4476/4885L3MBTL1 914/4885ALDH1A1 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback